Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed … – GlobeNewswire (press release)
GlobeNewswire (press release) |
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed …
GlobeNewswire (press release) engineered T-cells in a relapsed/refractory AML patient without preconditioning. MONT-SAINT-GUIBERT, Belgium, April 27, 2018 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical … |
